

Comprehensive detection of germline and somatic structural mutation in cancer genomes by Bionano Genomics Optical Mapping

A.W.C. Pang, J. Lee, K. Hong, T. Anantharaman, E.T. Lam, A. Hastie, M. Oldakowski
Bionano Genomics, San Diego, California, United States of America

Abstract

The ability to identify structural variants (SVs) is crucial in cancer genetics. Karyotype and cytogenetics are manually intensive. Microarrays and sequencing cannot detect calls in segmental duplications and repeats, miss balanced variants and low-frequency mutations.


We describe Bionano's Saphyr platform to identify SVs in cancer genomes. DNA >100 kbp is extracted, labeled at specific motifs, and linearized through NanoChannel arrays. Molecule images are digitized and *de novo* assembled, creating chromosomal-arm scale genome maps. Cancer mutations >500 bp are detected by aligning the molecules or the genome maps to the public reference.

We ran Bionano's cancer workflow on multiple human cancer cell lines. While the number of SVs varies among samples, we typically observe > 3,500 calls per genome. In the SK-BR-3 breast cancer genome, we detected a cluster of amplifications, and translocations on chr8, impacting the gene *MYC*. In the CML genome K562, the *BCR-ABL* translocation was detected, while we also detected novel rearrangements, such as insertion and inversion interrupting the gene *NAALADL2* in a prostate cancer cell line LNCaP. In conclusion, with one platform, Saphyr can discover a broad range of traditionally refractory but relevant SVs, and improves our understanding of cancer.


Background

Generating high-quality finished genomes replete with accurate identification of structural variation and high completion (minimal gaps) remains challenging using short read sequencing technologies alone. The Saphyr™ system provides direct visualization of long DNA molecules in their native state, bypassing the statistical inference needed to align paired-end reads with an uncertain insert size distribution. These long labeled molecules are *de novo* assembled into physical maps spanning the entire diploid genome. The resulting provides the ability to correctly position and orient sequence contigs into chromosome-scale scaffolds and detect a large range of homozygous and heterozygous structural variation with very high efficiency.

Methods



(1) Long molecules of DNA are labeled with Bionano reagents by (2) incorporation of fluorophores at a specific sequence motif throughout the genome. (3) The labeled genomic DNA is then linearized in the Saphyr Chip using NanoChannel arrays (4) Single molecules are imaged by Saphyr and then digitized. (5) Molecules are uniquely identifiable by distinct distribution of sequence motif labels (6) and then assembled by pairwise alignment into *de novo* genome maps.




Sample	SK-BR-3
Data collected (molecules >150 kb)	974 Gbp
Assembly size (haplotype-aware)	5.79 Gbp
Genome map N50	45.9 Mbp
SV called against hg38*	
Insertions	2256
Deletions	1057
Duplications	95
Inversions	148
Interchromosomal translocations	20
Intrachromosomal translocations	59


- Insertion
- Deletion
- Inversion
- Duplication
- Translocation
- CNV

Overview of SVs detected in a breast cancer sample


Change in molecule depth of coverage can identify amplifications and deletions




A 1.33 Mbp copy number amplification at the *MYC* region in SK-BR-3



Example of a translocation in SK-BR-3 missed by sequencing in the study Nattestad et al., 2018. With Bionano's long molecules, we were able to construct the translocation allele. We observe a 54 kbp novel sequences between the translocation junctions, and the one of the junctions coincides with segmental duplications.




A 790 kbp tandem duplication found in a breast cancer sample. The *de novo* assembly captured the duplication breakpoint, which indicates that *BRCA1* fused to *CD300LG*.



- BCR = Breakpoint Cluster Region Protein
- Associated with leukemia, both chronic myeloid (CML) and acute lymphoblastic (ALL)
- ABL = ABL Proto-Oncogene 1
- ABL fusion with BCR is a signature of chronic myeloid leukemia (CML)

The t(9;22) translocation detected in the chronic myeloid leukemia (CML) sample K-562. Note that the breakpoints are at *BCR* on chr22 and at *ABL1* on chr9.



In the LNCaP prostate cancer cell line, we found a 97 kbp inversion and a 113 kbp insertion overlap the *NAALADL2*, a gene associated with other congenital genetic diseases such as the Cornelia de Lange syndrome. Bionano optical maps can capture multiple events in a locus.

Conclusions

We demonstrate that the Saphyr system can be used to accurately detect genetic mutation hallmarks in samples with cancer. These include large rearrangements ranging from translocations, within chromosome fusions, to copy number alterations. Researchers can perform experiments to uncover somatic variation by comparing with Bionano control sample database, or against a matched pair sample. Furthermore, Bionano SV pipelines can detect SVs with complex breakpoint structures that are recalcitrant to detection by other technologies. Our results indicate that the Saphyr system can capture a broad spectrum of variation with functional importance, and can provide easy solutions for cancer studies.

References

- 1) Cao, H., et al., Rapid detection of structural variation in a human genome using NanoChannel-based genome mapping technology. *Gigascience* (2014); 3(1):34.
- 2) Hastie, A.R., et al. Rapid Genome Mapping in NanoChannel Arrays for Highly Complete and Accurate De Novo Sequence Assembly of the Complex *Aegilops tauschii* Genome. *PLoS ONE* (2013); 8(2): e55864.
- 3) Das, S. K., et al. Single molecule linear analysis of DNA in nano-channel labeled with sequence specific fluorescent probes. *Nucleic Acids Research* (2010); 38: 8.
- 4) Xiao, M et al. Rapid DNA mapping by fluorescent single molecule detection. *Nucleic Acids Research* (2007); 35:e16.
- 5) Nattestad, M. et al. Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNA sequencing of a breast cancer cell line. *Genome Research* (2018); 28:1126.